{"id":9318,"date":"2024-01-29T20:43:00","date_gmt":"2024-01-29T12:43:00","guid":{"rendered":"https:\/\/flcube.com\/?p=9318"},"modified":"2024-10-24T20:46:18","modified_gmt":"2024-10-24T12:46:18","slug":"shandong-boan-biotechnology-strikes-licensing-deal-with-joincare-for-long-acting-mab-ba2101","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=9318","title":{"rendered":"Shandong Boan Biotechnology Strikes Licensing Deal with Joincare for Long-Acting mAb BA2101"},"content":{"rendered":"\n<p>Shandong Boan Biotechnology Co., Ltd (HKG: 6955), based in China, has announced a licensing agreement with fellow Chinese firm Joincare Pharmaceutical Group Industry Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/600380:SHA\">SHA: 600380<\/a>) for its in-house developed long-acting monoclonal antibody (mAb) BA2101. According to the agreement, Joincare will obtain exclusive rights to develop, regulate, and commercialize BA2101 in mainland China for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Boan will retain all rights to the drug for non-respiratory indications in mainland China and all rights for all indications outside of mainland China.<\/p>\n\n\n\n<p>Joincare will make an undisclosed upfront payment to Boan, as well as pay development and sales milestone payments and royalties on sales. Joincare will also cover the costs for clinical study and development activities related to BA2101 for respiratory diseases in mainland China.<\/p>\n\n\n\n<p>BA2101 is an innovative long-acting human monoclonal IgG4 antibody that targets the interleukin-4 receptor subunit \u03b1 (IL-4R \u03b1). Administered subcutaneously with an expected four-week administration cycle, the drug can inhibit both the IL-4 and IL-13 signal pathways, regulate Th2 type inflammation, reduce eosinophil content and IgE levels, and treat allergic diseases caused by Th2 type inflammation. The intended indications for BA2101 include atopic dermatitis, asthma, chronic sinusitis with nasal polyps, prurigo nodosum, chronic spontaneous urticaria, and more.- <a href=\"https:\/\/flcube.com\">Flcube.com<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shandong Boan Biotechnology Co., Ltd (HKG: 6955), based in China, has announced a licensing agreement&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[30,220,1024,676,965],"class_list":["post-9318","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","category-drug","tag-biotech","tag-boan-biotechnology","tag-hkg-6955","tag-joincare-pharmaceutical","tag-sha-600380"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shandong Boan Biotechnology Strikes Licensing Deal with Joincare for Long-Acting mAb BA2101 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shandong Boan Biotechnology Co., Ltd (HKG: 6955), based in China, has announced a licensing agreement with fellow Chinese firm Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) for its in-house developed long-acting monoclonal antibody (mAb) BA2101. According to the agreement, Joincare will obtain exclusive rights to develop, regulate, and commercialize BA2101 in mainland China for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Boan will retain all rights to the drug for non-respiratory indications in mainland China and all rights for all indications outside of mainland China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=9318\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shandong Boan Biotechnology Strikes Licensing Deal with Joincare for Long-Acting mAb BA2101\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=9318\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-29T12:43:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-24T12:46:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9318#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9318\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shandong Boan Biotechnology Strikes Licensing Deal with Joincare for Long-Acting mAb BA2101\",\"datePublished\":\"2024-01-29T12:43:00+00:00\",\"dateModified\":\"2024-10-24T12:46:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9318\"},\"wordCount\":221,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotech\",\"Boan Biotechnology\",\"HKG: 6955\",\"Joincare Pharmaceutical\",\"SHA: 600380\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=9318#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9318\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=9318\",\"name\":\"Shandong Boan Biotechnology Strikes Licensing Deal with Joincare for Long-Acting mAb BA2101 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-01-29T12:43:00+00:00\",\"dateModified\":\"2024-10-24T12:46:18+00:00\",\"description\":\"Shandong Boan Biotechnology Co., Ltd (HKG: 6955), based in China, has announced a licensing agreement with fellow Chinese firm Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) for its in-house developed long-acting monoclonal antibody (mAb) BA2101. According to the agreement, Joincare will obtain exclusive rights to develop, regulate, and commercialize BA2101 in mainland China for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Boan will retain all rights to the drug for non-respiratory indications in mainland China and all rights for all indications outside of mainland China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9318#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=9318\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9318#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shandong Boan Biotechnology Strikes Licensing Deal with Joincare for Long-Acting mAb BA2101\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shandong Boan Biotechnology Strikes Licensing Deal with Joincare for Long-Acting mAb BA2101 - Insight, China&#039;s Pharmaceutical Industry","description":"Shandong Boan Biotechnology Co., Ltd (HKG: 6955), based in China, has announced a licensing agreement with fellow Chinese firm Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) for its in-house developed long-acting monoclonal antibody (mAb) BA2101. According to the agreement, Joincare will obtain exclusive rights to develop, regulate, and commercialize BA2101 in mainland China for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Boan will retain all rights to the drug for non-respiratory indications in mainland China and all rights for all indications outside of mainland China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=9318","og_locale":"en_US","og_type":"article","og_title":"Shandong Boan Biotechnology Strikes Licensing Deal with Joincare for Long-Acting mAb BA2101","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=9318","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-01-29T12:43:00+00:00","article_modified_time":"2024-10-24T12:46:18+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=9318#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=9318"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shandong Boan Biotechnology Strikes Licensing Deal with Joincare for Long-Acting mAb BA2101","datePublished":"2024-01-29T12:43:00+00:00","dateModified":"2024-10-24T12:46:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=9318"},"wordCount":221,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotech","Boan Biotechnology","HKG: 6955","Joincare Pharmaceutical","SHA: 600380"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=9318#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=9318","url":"https:\/\/flcube.com\/?p=9318","name":"Shandong Boan Biotechnology Strikes Licensing Deal with Joincare for Long-Acting mAb BA2101 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-01-29T12:43:00+00:00","dateModified":"2024-10-24T12:46:18+00:00","description":"Shandong Boan Biotechnology Co., Ltd (HKG: 6955), based in China, has announced a licensing agreement with fellow Chinese firm Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) for its in-house developed long-acting monoclonal antibody (mAb) BA2101. According to the agreement, Joincare will obtain exclusive rights to develop, regulate, and commercialize BA2101 in mainland China for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Boan will retain all rights to the drug for non-respiratory indications in mainland China and all rights for all indications outside of mainland China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=9318#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=9318"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=9318#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shandong Boan Biotechnology Strikes Licensing Deal with Joincare for Long-Acting mAb BA2101"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/9318","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=9318"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/9318\/revisions"}],"predecessor-version":[{"id":9319,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/9318\/revisions\/9319"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=9318"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=9318"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=9318"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}